We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958,
News

Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958,

Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958,
News

Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958,

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958,"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CS-8958 is a laninamivir prodrug that is a Long-Acting Neuraminidase Inhibitor.
The drug, developed entirely for the Japanese market by Daiichi Sankyo, will be
in the form of an inhalant that will directly treat the airways of influenza patients.
Clinical studies to date with adults and children suffering from type A or B influenza
viruses have proven CS-8958 to be effective with a single administration.

In non-clinical studies, CS-8958 has also demonstrated that it is efficacious with
the H1N1 and potentially lethal H5N1 (avian influenza) viruses, leading to an
expectation for wide-ranging contributions to influenza treatment in the future.

In November 2009, Daiichi Sankyo began a Phase III clinical study in Japan on
the prophylactic use of CS-8958.
Advertisement